Erratum: Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene (DOI:10.1016/j.cmet.2009.11.007);Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene

Cell Metabolism

Volumn 11, Issue 1, 2010, Pages 11-22

  Hedbacker, Kristina ^a   Birsoy, Kivanç ^a   Wysocki, Robert W ^a,b   Asilmaz, Esra ^a   Ahima, Rexford S ^c   Farooqi, I Sadaf ^d   Friedman, Jeffrey M ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

HUMDISEASE

Indexed keywords

LEPTIN; SOMATOMEDIN BINDING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; GENE OVEREXPRESSION; GENETIC REGULATION; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC REGULATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADENOVIRIDAE; MUS;

EID: 73049107663     PISSN: 15504131     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmet.2010.02.010     Document Type: Erratum

References (75)

1. Ahima R.S., Qi Y., Singhal N.S., Jackson M.B., and Scherer P.E. Brain adipocytokine action and metabolic regulation. Diabetes 55 Suppl 2 (2006) S145-S154
2. Akirav E.M., Chan O., Inouye K., Riddell M.C., Matthews S.G., and Vranic M. Partial leptin restoration increases hypothalamic-pituitary-adrenal activity while diminishing weight loss and hyperphagia in streptozotocin diabetic rats. Metabolism 53 (2004) 1558-1564
3. Arai T., Busby Jr. W., and Clemmons D.R. Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 137 (1996) 4571-4575
4. Asilmaz E., Cohen P., Miyazaki M., Dobrzyn P., Ueki K., Fayzikhodjaeva G., Soukas A.A., Kahn C.R., Ntambi J.M., Socci N.D., and Friedman J.M. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J. Clin. Invest. 113 (2004) 414-424
5. Balthasar N., Coppari R., McMinn J., Liu S.M., Lee C.E., Tang V., Kenny C.D., McGovern R.A., Chua Jr. S.C., Elmquist J.K., and Lowell B.B. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron 42 (2004) 983-991
6. Barzilai N., Wang J., Massilon D., Vuguin P., Hawkins M., and Rossetti L. Leptin selectively decreases visceral adiposity and enhances insulin action. J. Clin. Invest. 100 (1997) 3105-3110
7. Baxter R.C., and Martin J.L. Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog. Growth Factor Res. 1 (1989) 49-68
8. Birsoy K., Chen Z., and Friedman J. Transcriptional regulation of adipogenesis by KLF4. Cell Metab. 7 (2008) 339-347
9. Birsoy K., Soukas A., Torrens J., Ceccarini G., Montez J., Maffei M., Cohen P., Fayzikhodjaeva G., Viale A., Socci N.D., and Friedman J.M. Cellular program controlling the recovery of adipose tissue mass: An in vivo imaging approach. Proc. Natl. Acad. Sci. USA 105 (2008) 12985-12990
10. Burcelin R., Kamohara S., Li J., Tannenbaum G.S., Charron M.J., and Friedman J.M. Acute intravenous leptin infusion increases glucose turnover but not skeletal muscle glucose uptake in ob/ob mice. Diabetes 48 (1999) 1264-1269
11. Cauchi S., Meyre D., Durand E., Proença C., Marre M., Hadjadj S., Choquet H., De Graeve F., Gaget S., Allegaert F., et al. Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS ONE 3 (2008) e2031
12. Cauchi S., Proença C., Choquet H., Gaget S., De Graeve F., Marre M., Balkau B., Tichet J., Meyre D., Vaxillaire M., Froguel P., and D.E.S.I.R. Study Group. Analysis of novel risk loci for type 2 diabetes in a general French population: the D.E.S.I.R. study. J. Mol. Med. 86 (2008) 341-348
13. Chinookoswong N., Wang J.L., and Shi Z.Q. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 48 (1999) 1487-1492
14. Cochran E., Young J.R., Sebring N., DePaoli A., Oral E.A., and Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J. Clin. Endocrinol. Metab. 89 (2004) 1548-1554
15. Cohen P., Zhao C., Cai X., Montez J.M., Rohani S.C., Feinstein P., Mombaerts P., and Friedman J.M. Selective deletion of leptin receptor in neurons leads to obesity. J. Clin. Invest. 108 (2001) 1113-1121
16. Crossey P.A., Jones J.S., and Miell J.P. Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes 49 (2000) 457-465
17. Di Cola G., Cool M.H., and Accili D. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J. Clin. Invest. 99 (1997) 2538-2544
18. Dunger D., Yuen K., and Ong K. Insulin-like growth factor I and impaired glucose tolerance. Horm. Res. 62 Suppl 1 (2004) 101-107
19. Ebihara K., Ogawa Y., Masuzaki H., Shintani M., Miyanaga F., Aizawa-Abe M., Hayashi T., Hosoda K., Inoue G., Yoshimasa Y., et al. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50 (2001) 1440-1448
20. Ebihara K., Kusakabe T., Hirata M., Masuzaki H., Miyanaga F., Kobayashi N., Tanaka T., Chusho H., Miyazawa T., Hayashi T., et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J. Clin. Endocrinol. Metab. 92 (2007) 532-541
21. Farooqi I.S., and O'Rahilly S. Monogenic human obesity syndromes. Recent Prog. Horm. Res. 59 (2004) 409-424
22. Farooqi I.S., Jebb S.A., Langmack G., Lawrence E., Cheetham C.H., Prentice A.M., Hughes I.A., McCamish M.A., and O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341 (1999) 879-884
23. Farooqi I.S., Matarese G., Lord G.M., Keogh J.M., Lawrence E., Agwu C., Sanna V., Jebb S.A., Perna F., Fontana S., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110 (2002) 1093-1103
24. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23 (2002) 824-854
25. Froesch E.R., Bianda T., and Hussain M.A. Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance. Diabetes Metab. 22 (1996) 261-267
26. Grarup N., Rose C.S., Andersson E.A., Andersen G., Nielsen A.L., Albrechtsen A., Clausen J.O., Rasmussen S.S., Jørgensen T., Sandbaek A., et al. Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes 56 (2007) 3105-3111
27. Guler H.P., Zapf J., and Froesch E.R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N. Engl. J. Med. 317 (1987) 137-140
28. Gutiérrez-Juárez R., Obici S., and Rossetti L. Melanocortin-independent effects of leptin on hepatic glucose fluxes. J. Biol. Chem. 279 (2004) 49704-49715
29. Hertel J.K., Johansson S., Raeder H., Midthjell K., Lyssenko V., Groop L., Molven A., and Njølstad P.R. Genetic analysis of recently identified type 2 diabetes loci in 1,638 unselected patients with type 2 diabetes and 1,858 control participants from a Norwegian population-based cohort (the HUNT study). Diabetologia 51 (2008) 971-977
30. Hill J.W., Xu Y., Preitner F., Fukuda M., Cho Y.R., Luo J., Balthasar N., Coppari R., Cantley L.C., Kahn B.B., et al. Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis. Endocrinology 150 (2009) 4874-4882
31. Höflich A., Lahm H., Blum W., Kolb H., and Wolf E. Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett. 434 (1998) 329-334
32. Horikawa Y., Miyake K., Yasuda K., Enya M., Hirota Y., Yamagata K., Hinokio Y., Oka Y., Iwasaki N., Iwamoto Y., et al. Replication of genome-wide association studies of type 2 diabetes susceptibility in Japan. J. Clin. Endocrinol. Metab. 93 (2008) 3136-3141
33. Imai Y., Varela G.M., Jackson M.B., Graham M.J., Crooke R.M., and Ahima R.S. Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. Gastroenterology 132 (2007) 1947-1954
34. Jones J.I., and Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16 (1995) 3-34
35. Kamohara S., Burcelin R., Halaas J.L., Friedman J.M., and Charron M.J. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389 (1997) 374-377
36. Kelley K.M., Oh Y., Gargosky S.E., Gucev Z., Matsumoto T., Hwa V., Ng L., Simpson D.M., and Rosenfeld R.G. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int. J. Biochem. Cell Biol. 28 (1996) 619-637
37. Kelley K.M., Schmidt K.E., Berg L., Sak K., Galima M.M., Gillespie C., Balogh L., Hawayek A., Reyes J.A., and Jamison M. Comparative endocrinology of the insulin-like growth factor-binding protein. J. Endocrinol. 175 (2002) 3-18
38. Kovacs G.T., Worgall S., Schwalbach P., Steichele T., Mehls O., and Rosivall L. Hypoglycemic effects of insulin-like growth factor-1 in experimental uremia: can concomitant growth hormone administration prevent this effect?. Horm. Res. 51 (1999) 193-200
39. Kowalski T.J., Liu S.M., Leibel R.L., and Chua Jr. S.C. Transgenic complementation of leptin-receptor deficiency. I. Rescue of the obesity/diabetes phenotype of LEPR-null mice expressing a LEPR-B transgene. Diabetes 50 (2001) 425-435
40. Levin N., Nelson C., Gurney A., Vandlen R., and de Sauvage F. Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proc. Natl. Acad. Sci. USA 93 (1996) 1726-1730
41. Lin S., Thomas T.C., Storlien L.H., and Huang X.F. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int. J. Obes. Relat. Metab. Disord. 24 (2000) 639-646
42. Liu L., Karkanias G.B., Morales J.C., Hawkins M., Barzilai N., Wang J., and Rossetti L. Intracerebroventricular leptin regulates hepatic but not peripheral glucose fluxes. J. Biol. Chem. 273 (1998) 31160-31167
43. Martin J.L., and Baxter R.C. Insulin-like growth factor-binding protein from human plasma. Purification and characterization. J. Biol. Chem. 261 (1986) 8754-8760
44. Miles P.D., Yamatani K., Lickley H.L., and Vranic M. Mechanism of glucoregulatory responses to stress and their deficiency in diabetes. Proc. Natl. Acad. Sci. USA 88 (1991) 1296-1300
45. Montague C.T., Farooqi I.S., Whitehead J.P., Soos M.A., Rau H., Wareham N.J., Sewter C.P., Digby J.E., Mohammed S.N., Hurst J.A., et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387 (1997) 903-908
46. Morton G.J., Gelling R.W., Niswender K.D., Morrison C.D., Rhodes C.J., and Schwartz M.W. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab. 2 (2005) 411-420
47. Muzzin P., Eisensmith R.C., Copeland K.C., and Woo S.L. Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. Proc. Natl. Acad. Sci. USA 93 (1996) 14804-14808
48. Obici S., Feng Z., Tan J., Liu L., Karkanias G., and Rossetti L. Central melanocortin receptors regulate insulin action. J. Clin. Invest. 108 (2001) 1079-1085
49. Oral E.A., Simha V., Ruiz E., Andewelt A., Premkumar A., Snell P., Wagner A.J., DePaoli A.M., Reitman M.L., Taylor S.I., et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346 (2002) 570-578
50. Pelleymounter M.A., Cullen M.J., Baker M.B., Hecht R., Winters D., Boone T., and Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269 (1995) 540-543
51. Petersen K.F., Oral E.A., Dufour S., Befroy D., Ariyan C., Yu C., Cline G.W., DePaoli A.M., Taylor S.I., Gorden P., and Shulman G.I. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109 (2002) 1345-1350
52. Pintar J.E., Schuller A., Cerro J.A., Czick M., Grewal A., and Green B. Genetic ablation of IGFBP-2 suggests functional redundancy in the IGFBP family. Prog. Growth Factor Res. 6 (1995) 437-445
53. Pocai A., Lam T.K., Gutierrez-Juarez R., Obici S., Schwartz G.J., Bryan J., Aguilar-Bryan L., and Rossetti L. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 434 (2005) 1026-1031
54. Prpic V., Watson P.M., Frampton I.C., Sabol M.A., Jezek G.E., and Gettys T.W. Differential mechanisms and development of leptin resistance in A/J versus C57BL/6J mice during diet-induced obesity. Endocrinology 144 (2003) 1155-1163
55. Qi Y., Nie Z., Lee Y.S., Singhal N.S., Scherer P.E., Lazar M.A., and Ahima R.S. Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 55 (2006) 3083-3090
56. Rajkumar K., Modric T., and Murphy L.J. Impaired adipogenesis in insulin-like growth factor binding protein-1 transgenic mice. J. Endocrinol. 162 (1999) 457-465
57. Rosenzweig S.A. What's new in the IGF-binding proteins?. Growth Horm. IGF Res. 14 (2004) 329-336
58. Rossetti L., Massillon D., Barzilai N., Vuguin P., Chen W., Hawkins M., Wu J., and Wang J. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J. Biol. Chem. 272 (1997) 27758-27763
59. Russo V.C., Schütt B.S., Andaloro E., Ymer S.I., Hoeflich A., Ranke M.B., Bach L.A., and Werther G.A. Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146 (2005) 4445-4455
60. Sadri P., and Lautt W.W. Glucose disposal by insulin, but not IGF-1, is dependent on the hepatic parasympathetic nerves. Can. J. Physiol. Pharmacol. 78 (2000) 807-812
61. Sanghera D.K., Ortega L., Han S., Singh J., Ralhan S.K., Wander G.S., Mehra N.K., Mulvihill J.J., Ferrell R.E., Nath S.K., and Kamboh M.I. Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk. BMC Med. Genet. 9 (2008) 59
62. Saxena R., Voight B.F., Lyssenko V., Burtt N.P., de Bakker P.I., Chen H., Roix J.J., Kathiresan S., Hirschhorn J.N., Daly M.J., et al., Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316 (2007) 1331-1336
63. Schwartz M.W., Baskin D.G., Bukowski T.R., Kuijper J.L., Foster D., Lasser G., Prunkard D.E., Porte Jr. D., Woods S.C., Seeley R.J., and Weigle D.S. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 45 (1996) 531-535
64. Scott L.J., Mohlke K.L., Bonnycastle L.L., Willer C.J., Li Y., Duren W.L., Erdos M.R., Stringham H.M., Chines P.S., Jackson A.U., et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316 (2007) 1341-1345
65. Shimomura I., Hammer R.E., Ikemoto S., Brown M.S., and Goldstein J.L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401 (1999) 73-76
66. Takahashi N., Qi Y., Patel H.R., and Ahima R.S. A novel aminosterol reverses diabetes and fatty liver disease in obese mice. J. Hepatol. 41 (2004) 391-398
67. van de Wall E., Leshan R., Xu A.W., Balthasar N., Coppari R., Liu S.M., Jo Y.H., MacKenzie R.G., Allison D.B., Dun N.J., et al. Collective and individual functions of leptin receptor modulated neurons controlling metabolism and ingestion. Endocrinology 149 (2008) 1773-1785
68. Van Heek M., Compton D.S., France C.F., Tedesco R.P., Fawzi A.B., Graziano M.P., Sybertz E.J., Strader C.D., and Davis Jr. H.R. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J. Clin. Invest. 99 (1997) 385-390
69. Vranic M., Kawamori R., Pek S., Kovacevic N., and Wrenshall G.A. The essentiality of insulin and the role of glucagon in regulating glucose utilization and production during strenuous exercise in dogs. J. Clin. Invest. 57 (1976) 245-255
70. Wheatcroft S.B., Kearney M.T., Shah A.M., Ezzat V.A., Miell J.R., Modo M., Williams S.C., Cawthorn W.P., Medina-Gomez G., Vidal-Puig A., et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 56 (2007) 285-294
71. Wolf E., Lahm H., Wu M., Wanke R., and Hoeflich A. Effects of IGFBP-2 overexpression in vitro and in vivo. Pediatr. Nephrol. 14 (2000) 572-578
72. Wood T.L., Rogler L., Streck R.D., Cerro J., Green B., Grewal A., and Pintar J.E. Targeted disruption of IGFBP-2 gene. Growth Regul. 3 (1993) 5-8
73. Yu X., Park B.H., Wang M.Y., Wang Z.V., and Unger R.H. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc. Natl. Acad. Sci. USA 105 (2008) 14070-14075
74. Zeggini E., Weedon M.N., Lindgren C.M., Frayling T.M., Elliott K.S., Lango H., Timpson N.J., Perry J.R., Rayner N.W., Freathy R.M., et al., Wellcome Trust Case Control Consortium (WTCCC). Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316 (2007) 1336-1341
75. Zenobi P.D., Glatz Y., Keller A., Graf S., Jaeggi-Groisman S.E., Riesen W.F., Schoenle E.J., and Froesch E.R. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur. J. Endocrinol. 131 (1994) 251-257